FRANKLIN, Mass., Jan. 8 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (Nasdaq: SONT) (OTC: SONT.PK) announced today that in
connection with its previously announced decision to voluntarily delist
from the Nasdaq Capital Market, on January 8, 2007, Nasdaq suspended the
quotation of Sontra's common stock. Although the quotation of Sontra's
common stock has been suspended, Sontra will remain subject to Nasdaq rules
until its delisting is effective on January 18, 2007.
As of January 8, 2007, the Company's quotation for its common stock is
expected to appear in the "Pink Sheets" under the symbol "SONT." The
Company's common stock may also be quoted in the future on the OTC Bulletin
Board provided a market maker files the necessary application with the NASD
and such application is cleared. Following its delisting from Nasdaq, the
Company expects to remain a public company and to continue to make its
required SEC filings.
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation, a technology leader in transdermal science,
has been developing a non-invasive, continuous transdermal glucose monitor
("CTGM") for principal use in the Intensive Care Market. In addition, the
Company owns a platform technology, the SonoPrep(R) Permeation System, and
other technology for transdermal delivery of large molecule drugs and
vaccines.
SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks
or registered trademarks of their respective owners.
Investor Relations Contacts:
Harry G. Mitchell, Interim CEO
508-530-0311
hmitchell@sontra.com
SOURCE Sontra Medical Corporation
 back to top
Related links:
http://www.sontra.com
CONTACT:
Harry G. Mitchell, Interim CEO of Sontra
Medical Corporation, +1-508-530-0311, or hmitchell@sontra.com
|
